News und Analysen
EQS-News: Eckert & Ziegler Gains Approval for GalliaPharm® in Japan
EQS-News: Eckert & Ziegler Gains Approval for GalliaPharm® in Japan
New Research in a New England Journal of Medicine Publication Finds Patients of Value-Based Care Organizations Have More Frequent and Consistent Primary Care Visits
A new study published in The New England Journal of Medicine Catalyst, conducted by the Humana Healthcare Research team and Massachusetts General Hospital Attending Physician Dr. Suhas Gondi, who
Sensorion Reports 2025 Half-Year Results, Provides Corporate Update and Announces Availability of Half-Year Report
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss
EQS-News: Horus Pharma becomes additional commercialization partner for Formycon's Eylea® biosimilar FYB203 in selected European countries under the brand name Baiama®
EQS-News: Horus Pharma becomes additional commercialization partner for Formycon's Eylea® biosimilar FYB203 in selected European countries under the brand name Baiama®
EQS-Adhoc: FamiCord AG: Polski Bank Komórek Macierzystych sp. z o. o. is to acquire 100 % in stem cell bank “nOvum” spółka z ograniczoną odpowiedzialnością, Warsaw, Poland
EQS-Adhoc: FamiCord AG: Polski Bank Komórek Macierzystych sp. z o. o. is to acquire 100 % in stem cell bank “nOvum” spółka z ograniczoną odpowiedzialnością, Warsaw, Poland
EQS-News: MPH Health Care AG publishes figures for the first half-year of 2025: Equity (NAV) amounts to EUR 205.1 million, which corresponds to EUR 47.91 per share. The equity ratio fell slightly to 93.7%
EQS-News: MPH Health Care AG publishes figures for the first half-year of 2025: Equity (NAV) amounts to EUR 205.1 million, which corresponds to EUR 47.91 per share. The equity ratio fell slightly to 93.7%
Eric Bernard takes over as Sonova CEO effective September 15, 2025
Eric Bernard takes over as Sonova CEO effective September 15, 2025
EQS-News: Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
EQS-News: Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
Uni-Bio Science Group and Kexing Biopharm Forge Strategic Partnership to Accelerate Global Expansion of Osteoporosis Treatment Bogutai®
Uni-Bio Science Group and Kexing Biopharm Forge Strategic Partnership to Accelerate Global Expansion of Osteoporosis Treatment Bogutai®
Lonza Appoints Jason Berndt as Head of Group Operations, and Maria Soler Nunez as Chief Quality Officer
Lonza Appoints Jason Berndt as Head of Group Operations, and Maria Soler Nunez as Chief Quality Officer
EQS-News: Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis
EQS-News: Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis
EQS-News: Eckert & Ziegler: Berenberg Starts Coverage with a “Buy” Recommendation and a Price Target of € 24 – Price Potential 47%
EQS-News: Eckert & Ziegler: Berenberg Starts Coverage with a “Buy” Recommendation and a Price Target of € 24 – Price Potential 47%
EQS-News: M1 Kliniken AG: Successful First Half of 2025 with EBIT Growth of 24% and Earnings per Share of EUR 0.63
EQS-News: M1 Kliniken AG: Successful First Half of 2025 with EBIT Growth of 24% and Earnings per Share of EUR 0.63
EQS-News: Abivax Presents First Half 2025 Financial Results
EQS-News: Abivax Presents First Half 2025 Financial Results
Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula
Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced positive topline results from an ongoing Phase 3 clinical trial cohort evaluating the safety
EQS-News: Immunic to Participate in Investor and Scientific Conferences in September
EQS-News: Immunic to Participate in Investor and Scientific Conferences in September
EQS-News: Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2025
EQS-News: Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2025
EQS-News: BRAIN Biotech AG appoints Johan Jansén-Storbacka as Executive Vice President of the BRAINBiocatalysts´ enzyme products business
EQS-News: BRAIN Biotech AG appoints Johan Jansén-Storbacka as Executive Vice President of the BRAINBiocatalysts´ enzyme products business
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Uni-Bio Science Group Announces 2025 Interim Results
Uni-Bio Science Group Announces 2025 Interim Results
EQS-Adhoc: MAQUET Medical Systems AG submitted specified squeeze-out request and has determined cash compensation for minority shareholders of Pulsion Medical Systems SE to be EUR 20.57
EQS-Adhoc: MAQUET Medical Systems AG submitted specified squeeze-out request and has determined cash compensation for minority shareholders of Pulsion Medical Systems SE to be EUR 20.57
EQS-News: BRAIN Biotech reports dynamic Q3 revenue growth in core segment BRAINBiocatalysts
EQS-News: BRAIN Biotech reports dynamic Q3 revenue growth in core segment BRAINBiocatalysts
EQS-Adhoc: Heidelberg Pharma’s Partner Telix Pharmaceuticals Gives Regulatory Update for its Imaging Agent TLX250-CDx
EQS-Adhoc: Heidelberg Pharma’s Partner Telix Pharmaceuticals Gives Regulatory Update for its Imaging Agent TLX250-CDx
Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19
Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application
Humana Announces New Agreements to Expand Specialized Care Programs for Patients Living with Musculoskeletal Conditions
Leading health and well-being company Humana Inc. (NYSE: HUM) today announced new strategic, individual value-based care partnerships with Vori Health and HOPCo, in addition to the company’s